camptothecin has been researched along with cysteine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, IK; Kang, MR; Muller, MT | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| Azrak, RG; Cao, S; Durrani, FA; Frank, C; Li, ZR; Rustum, YM; Yin, MB | 1 |
| Azrak, RG; Cao, S; Durrani, FA; Li, X; McLeod, HL; Pendyala, L; Rustum, YM; Shannon, WD; Smith, PF; Yu, J | 1 |
| Cao, S; Durrani, FA; Fakih, M; Rustum, YM | 1 |
| Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Frank, C; Hapke, G; Li, ZR; Rustum, YM; Tóth, K; Yin, MB | 1 |
| Ewis, HE; Liu, P; Lu, CD; Tai, PC; Weber, IT | 1 |
| Azrak, RG; Cao, S; Combs, GF; Durrani, FA; Fakih, M; Pendyala, L; Prey, J; Rustum, YM; Smith, PF | 1 |
| Bjornsti, MA; Douat-Casassus, C; Montaudon, D; Palle, K; Pourquier, P; Quideau, S; Rivory, LP; Robert, J | 1 |
| Doneanu, CE; Niture, SK; Pattabiraman, N; Srivenugopal, KS; Velu, CS | 1 |
| Bhattacharya, A; Cao, S; Chintala, S; Durrani, FA; Rustum, YM; Slocum, HK; Tóth, K | 1 |
| Cao, S; Chintala, S; Durrani, FA; Jensen, RL; Rustum, YM; Tóth, K; Vaughan, MM | 1 |
| Chen, B; Zhang, X | 1 |
| Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Rustum, YM; Toth, K | 1 |
| Francesconi, S; Girard, PM; Graindorge, D; Rigolet, P; Sage, E; Scanlon, S; Smirnova, V | 1 |
| Agatsuma, T | 1 |
2 review(s) available for camptothecin and cysteine
| Article | Year |
|---|---|
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine; Drug Synergism; Humans; Irinotecan; Mice; Neoplasms; Organoselenium Compounds; Rats; Selenocysteine; Selenomethionine | 2005 |
Development of New ADC Technology with Topoisomerase I Inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Cysteine; Drug Delivery Systems; Drug Discovery; Humans; Immunoconjugates; Molecular Targeted Therapy; Rats; Receptor, ErbB-2; Topoisomerase I Inhibitors; Trastuzumab | 2017 |
14 other study(ies) available for camptothecin and cysteine
| Article | Year |
|---|---|
Telomeric DNA damage by topoisomerase I. A possible mechanism for cell killing by camptothecin.
Topics: Apoptosis; Binding Sites; Biological Assay; Camptothecin; Cysteine; DNA; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Genome; HeLa Cells; Humans; Models, Biological; Plasmids; Potassium; Scleroderma, Localized; Sodium Dodecyl Sulfate; Telomere | 2004 |
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organoselenium Compounds; Radiation-Sensitizing Agents; Selenium; Selenocysteine; Selenomethionine; Time Factors | 2004 |
Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carbon-Sulfur Lyases; Caspase 3; Caspases; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Cysteine; DNA Fragmentation; Drug Interactions; Enzyme Activation; Gene Expression; Humans; Irinotecan; Minichromosome Maintenance Complex Component 2; Nuclear Proteins; Organoselenium Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Saccharomyces cerevisiae Proteins; Selenocysteine | 2004 |
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cysteine; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Pharmacogenetics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Selenocysteine; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiog
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cysteine; Down-Regulation; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Organoselenium Compounds; Selenocysteine; Transplantation, Heterologous | 2006 |
Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Bacillaceae; Binding Sites; Camptothecin; Carboxylesterase; Crystallization; Crystallography; Cysteine; Iodine; Irinotecan; Models, Molecular; Prodrugs; Protein Conformation | 2007 |
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
Topics: Administration, Oral; Animals; Bone Marrow; Camptothecin; Cysteine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Kidney; Kinetics; Liver; Mice; Mice, Nude; Neoplasms; Organoselenium Compounds; Plasma; Selenium; Selenocysteine | 2007 |
Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505.
Topics: Arsenicals; Camptothecin; Cysteine; DNA Cleavage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Ethylmaleimide; Humans; Mutagenesis, Site-Directed; Protein Conformation; Sulfhydryl Compounds; Topoisomerase I Inhibitors | 2007 |
Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress.
Topics: Acetylcysteine; Amino Acid Sequence; Binding Sites; Buthionine Sulfoximine; Camptothecin; Cell Line, Tumor; Cross-Linking Reagents; Cysteine; Diamide; DNA Damage; DNA-Binding Proteins; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Glutaral; Glutathione; Glutathione Disulfide; Humans; Hydrogen Peroxide; Models, Molecular; Oxidative Stress; Phosphorylation; Recombinant Proteins; Tandem Mass Spectrometry; tert-Butylhydroperoxide; Tumor Suppressor Protein p53 | 2007 |
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cysteine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forkhead Transcription Factors; Head and Neck Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Organoselenium Compounds; Selenocysteine; Tirapazamine; Triazines; Xenograft Model Antitumor Assays | 2008 |
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Cell Hypoxia; Cysteine; Drug Delivery Systems; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Reactive Oxygen Species; RNA, Small Interfering; Selenocysteine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin.
Topics: Animals; Apolipoprotein A-I; Camptothecin; Cysteine; Drug Carriers; Female; HCT116 Cells; Humans; Lipoproteins, HDL; Mice; Mice, Inbred BALB C; Nanoparticles; Pharmaceutical Vehicles; Recombinant Fusion Proteins; Tissue Distribution | 2010 |
Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Chromatography, High Pressure Liquid; Cysteine; Drug Synergism; Female; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Organoselenium Compounds; Selenocysteine; Xenograft Model Antitumor Assays | 2011 |
Oxidative stress in mammalian cells impinges on the cysteines redox state of human XRCC3 protein and on its cellular localization.
Topics: Animals; Camptothecin; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Cysteine; DNA Damage; DNA Repair; DNA Replication; DNA-Binding Proteins; Homologous Recombination; Humans; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species | 2013 |